Last updated 23 days ago
A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1
285 patients around the world
Available in Argentina, United States, Spain
BioNTech SE
28Research sites
285Patients around the world
This study is for people with
Head and neck cancer
Squamous cell carcinoma of the head and neck
Requirements for the patient
From 18 Years
All Gender
Medical requirements
Sites
Perdriel 74, CABA, Buenos Aireshttps://www.hospitalbritanico.org.ar/
25 de mayo 174, Viedma, Río Negrowww.imoviedma.com.ar
Dorrego 269, La Rioja
Calle 12 Nro 4756, Berazategui, Buenos Aires
Av Sarmiento 157, San Miguel de Tucumán
Antonio Varas 517, 7500653 Providencia, Región Metropolitana
Av. Madero y Gonzalitos S/N, Mitras Centro, Monterrey, Nuevo Leónhttp://www.medicina.uanl.mx/hu/
Miguel Hidalgo y Costilla 1828 Poniente, Obispado, 64060 Monterrey, N.L.
Calle 7 No 552 entre 24 A y 24 B Colonia Maya, Mérida, Yucatán
Bugambilias 30, La Riviera, 70050 Juchitán de Zaragoza, Oaxaca
Ejército Mexicano 3700, El Bajo, Chihuahua
C. de Villarroel, 170, 08036 Barcelona, Spainhttps://www.clinicbarcelona.org/
C. Joaquín Rodrigo, 1, 28222 Majadahonda, Madrid, Spain
StudyAHEAD-MERIT
SponsorBioNTech SE
Study typeInterventional
Conditions
Head and neck cancerSquamous cell carcinoma of the head and neck
Requirements
From 18 YearsAll Gender
Unique study IDclinicaltrials.gov
NCT04534205
